Nalaganje...
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase 3 study A...
Shranjeno v:
| izdano v: | Blood Cancer J |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5436074/ https://ncbi.nlm.nih.gov/pubmed/28430175 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.31 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|